These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 3571446)

  • 1. The rationale for a post-marketing surveillance.
    Westerholm B
    Hum Reprod; 1987 Jan; 2(1):41-4. PubMed ID: 3571446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden.
    Wiholm BE; Westerholm B
    Acta Med Scand Suppl; 1984; 683():107-17. PubMed ID: 6430038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmarketing evaluations help determine contraceptive safety, efficacy.
    Netw Res Triangle Park N C; 1988; 9(2):1-2, 7. PubMed ID: 12280950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal adverse drug reactions of anticancer drugs detected by all-case post-marketing surveillance in Japan.
    Mori J; Tanimoto T; Miura Y; Kami M
    Jpn J Clin Oncol; 2015 Jun; 45(6):588-94. PubMed ID: 25759486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing surveillance of drugs. The spontaneous reporting scheme: role of the Adverse Drug Reactions Advisory Committee.
    Roeser HP; Rohan AP
    Med J Aust; 1990 Dec 3-17; 153(11-12):720-6. PubMed ID: 2099761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy exposure registries.
    Kennedy DL; Uhl K; Kweder SL
    Drug Saf; 2004; 27(4):215-28. PubMed ID: 15003034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies.
    Spelsberg A; Prugger C; Doshi P; Ostrowski K; Witte T; Hüsgen D; Keil U;
    BMJ; 2017 Feb; 356():j337. PubMed ID: 28174182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses.
    Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C
    Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-marketing surveillance of oral contraceptives.
    Alberman E
    Hum Reprod; 1986 Nov; 1(7):433-4. PubMed ID: 3106401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005].
    Weisser K; Meyer C; Petzold D; Mentzer D; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Nov; 50(11):1404-17. PubMed ID: 17999134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance].
    Cossmann M; Kohnen C; Langford R; McCartney C
    Drugs; 1997; 53 Suppl 2():50-62. PubMed ID: 9190325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse event detection in drug development: recommendations and obligations beyond phase 3.
    Berlin JA; Glasser SC; Ellenberg SS
    Am J Public Health; 2008 Aug; 98(8):1366-71. PubMed ID: 18556607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epidemiological evaluation of drugs.
    Shapiro S
    Acta Med Scand Suppl; 1984; 683():23-7. PubMed ID: 6588735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-marketing evaluation of fertility-regulating drugs, as viewed by regulatory authorities.
    Hum Reprod; 1987 Jan; 2(1):45-58. PubMed ID: 3571447
    [No Abstract]   [Full Text] [Related]  

  • 15. Postmarketing analysis of medicines: methodology and value of the spanish case-control study and surveillance system in preventing birth defects.
    Martínez-Frías ML
    Drug Saf; 2007; 30(4):307-16. PubMed ID: 17408307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring outcomes of pregnancy following drug exposure: a company-based pregnancy registry program.
    Shields KE; Wiholm BE; Hostelley LS; Striano LF; Arena SR; Sharrar RG
    Drug Saf; 2004; 27(6):353-67. PubMed ID: 15144230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription-event monitoring: methodology and recent progress.
    Rawson NS; Pearce GL; Inman WH
    J Clin Epidemiol; 1990; 43(5):509-22. PubMed ID: 2324790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Surveillance and assessment of undesirable effects in drug treatment: pilot project].
    Hannig M; Hanpft R
    Soz Praventivmed; 1989; 34(6):272-7. PubMed ID: 2575309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing surveillance or drug acceptability study?
    Barnett DB; Woods KL
    Br J Clin Pharmacol; 1987 Sep; 24(3):281-2. PubMed ID: 3663444
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.